Previous 10 | Next 10 |
Global Blood Therapeutics (GBT): Q1 GAAP EPS of -$1.21 misses by $0.20.Revenue of $39.04M (+176.5% Y/Y) misses by $3.96M.Shares -2.33%.Press Release For further details see: Global Blood Therapeutics EPS misses by $0.20, misses on revenue
Achieved Oxbryta ® (voxelotor) net revenues of $39.0 million; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe Advanced pipeline programs inclacumab and GBT021601 (GBT601) and expanded pipeline with in-license of two novel small m...
SOUTH SAN FRANCISCO, Calif. and HANOVER, Md., May 04, 2021 (GLOBE NEWSWIRE) -- In recognition of World Sickle Cell Day, which falls on June 19, 2021, Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) today launched ...
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after U.S. financial markets close. Management will host a c...
Global Blood Therapeutics reported a strong Q4/2020 despite COVID-19 headwinds. The company's flagship product, Oxbryta, is off to a great start with a solid base moving into 2021. Shortly after Oxbryta's approval, I decided to book some profits and sock drawer the rest of the positio...
Global Blood Therapeutics (GBT) announces that The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta (voxelotor) tablets in patients with sickle cell disease ((SCD)).The results showed significant and sustained improvement in he...
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta ® (voxelotor) tablets in...
SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease (SCD) expert, to the company’s board of d...
Global Blood Therapeutics ([[GBT]] -2.4%) announces that it has entered into an agreement with Sanofi S.A. to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease ((SCD)), for upfront and milestone payments that could go up to $353M.The...
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced it has entered into an agreement with Sanofi S.A. to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease (S...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...